NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 313 filers reported holding NOVOCURE LTD in Q4 2022. The put-call ratio across all filers is 1.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $310,571 | -9.7% | 5,164 | +14.2% | 0.02% | -25.0% |
| Q3 2022 | $344,000 | +15.1% | 4,522 | +5.2% | 0.02% | +17.6% |
| Q2 2022 | $299,000 | -16.5% | 4,298 | -0.5% | 0.02% | 0.0% |
| Q1 2022 | $358,000 | +6.5% | 4,318 | -3.5% | 0.02% | 0.0% |
| Q4 2021 | $336,000 | -37.1% | 4,473 | -2.7% | 0.02% | -43.3% |
| Q3 2021 | $534,000 | -53.1% | 4,595 | -10.4% | 0.03% | -51.6% |
| Q2 2021 | $1,138,000 | +69.6% | 5,130 | +1.0% | 0.06% | +55.0% |
| Q1 2021 | $671,000 | -24.4% | 5,078 | -0.9% | 0.04% | -33.3% |
| Q4 2020 | $887,000 | +63.4% | 5,126 | +5.0% | 0.06% | +46.3% |
| Q3 2020 | $543,000 | +56.5% | 4,880 | -16.7% | 0.04% | +10.8% |
| Q2 2020 | $347,000 | – | 5,858 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |